x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

pharmaphorum Podcast

pharmaphorum is one of the leading global channels for insight into the pharma and healthcare industry – and is essentially a group of passionate people who like asking excellent questions. Our podcasts offer a chance to pose some of these questions to the keenest minds in our industry to look at the big issues and opportunities facing pharma, biotech and healthcare today. With interviews and contributions from a host of industry experts and insiders, the pharmaphorum podcast is a must-listen for

science life sciences

All Episodes

26:23

Unpacking Trumps executive order on drug pricing with...

pharmaphorum Podcast ·

2025/05/02

President Donald Trump’s April 15th executive order, “Lowering Drug Prices by Once Again Putting Americans First”, contained a smorgasbord of policy proposals targeting a variety of industry stakeholders.But how much legal force do these different elements have, and what are the concrete takeaways for pharma? To answer these questions and more, host Jonah Comstock once again welcomes Hogan Lovells attorney Alice Valder Curran to the podcast to pick apart the order piece by piece. They discuss the

en-us

12:05

AI in drug development: The real hurdle is...

pharmaphorum Podcast ·

2025/05/01

It can take up to 15 years for a new drug to reach the market, and with only 20% of pharmaceutical professionals adopting AI, one thing is clear: innovation in drug development is lagging behind. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Andrew Stelzer, head of business development at Unlearn.AI, about how the real hurdle in clinical research lies in effectively integrating AI. Stelzer discusses the need for greater coordination within the pharmaceutical industry,

en-us

24:02

Patients as active consumers of care: AI-driven...

pharmaphorum Podcast ·

2025/04/29

Therapy initiation, adherence, and health outcomes are being driven by artificial intelligence (AI)-powered personalisation. Today’s consumers are more active participants in their healthcare. Marketing in the era of consumer-driven healthcare requires new strategies to reach patients with the information they require, and how and when they need it. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Bill Grambley, CEO of AllazoHealth, for a conversation on leveraging AI for

en-us

18:42

Driving the drug discovery pipeline: The value of...

pharmaphorum Podcast ·

2025/04/22

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Tomasz Kostriezewski, CSO at CN Bio, about single organ-on-a-chip technology and multi-organ microphysiological systems (MPS), as well as accelerating drug discovery pipelines with these new alternative methodologies (NAMs).Clinical trial success rates are very low, with up to 95% not succeeding, and a wide range of disease states remains untreated. What NAMs permit is a screening of new drugs, of whatever entity – chemical or

en-us

15:10

Intelligent regulatory compliance and improved...

pharmaphorum Podcast ·

2025/04/16

Across the life sciences, Regulatory Affairs (RA) teams and their colleagues in Quality and Safety are stretched beyond their limits as already impossible demands on their time are compounded by rising health authority expectations.In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Sonia A. Veluchamy, CEO and co-founder of Celegence, a company dedicated to improving patient outcomes through intelligent regulatory compliance. For both pharma and medical device companies, time and

en-us

15:13

Prevention for a healthier, more productive society

pharmaphorum Podcast ·

2025/04/15

In a new pharmaphorum podcast, recorded during Anthropy 2025: Rebooting Britain, web editor Nicole Raleigh spoke with David Gillen, chief medical officer at Norgine, about the role of prevention in the future of healthcare. Recorded onsite at The Eden Project in Cornwall, the conversation centred around the Adelphi Group-sponsored panel, ‘The Prevention Revolution in Your Healthcare’, exploring the key takeaways and exciting possibilities from the panel discussion. Prevention is increasingly seen as

en-us

13:37

Safeguarding the pharmaceutical supply chain

pharmaphorum Podcast ·

2025/04/02

As we hear of the volcanic and seismic activity taking place in Iceland this week, pharmaphorum turns back to a conversation with Dean Alms, CPO of Aravo, on how extreme weather highlights the need to make adequate supply chain preparations for the seasons in which the planet pulls out all the stops with the worst of its natural disasters. Having a blueprint for supply chain resiliency is critical, as a mature and robust risk programme enables the right emergency protocols and drug reserves to be

en-us

35:49

For the continuum of mental health we need a whole...

pharmaphorum Podcast ·

2025/03/31

If we don’t address the mental health of young people, that mental health challenge will advance into the adult population of tomorrow. What can be done to address the issue, though? At Anthropy 2025: Rebooting Britain, web editor Nicole Raleigh sat down with Dr Sebastian Vaughn, CEO of Phytome Life Sciences, for an en plein air and explorative conversation around the topic, live onsite at The Eden Project in Cornwall, following the Adelphi sponsored panel, ‘Revolutionary Thinking for Mental

en-us

38:29

IRA updates and making sense of the chaos in...

pharmaphorum Podcast ·

2025/03/20

Last year, Alice Valder Curran, a partner at Hogan Lovells and a healthcare policy expert in Washington, D.C. joined host Jonah Comstock on the pharmaphorum podcast to talk about the intended and unintended consequences of the drug pricing negotiation provisions in the Inflation Reduction Act.On today’s episode, Curran joins us once again for an update on the IRA, looking at the second batch of drugs announced in January, recent messaging from the Centers for Medicare and Medicaid Services and what

en-us

11:05

GenAI and the revolution of drug development

pharmaphorum Podcast ·

2025/03/05

It takes around seven years to develop a new drug and bring it to market. With the advent of GenAI, businesses in the life sciences sector can speed up the process, wiping months or even years off that average. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Bryan Hill, life sciences chief technology officer at Cognizant, in a conversation on how generative AI is revolutionising life sciences and drug development. Though it might seem an obvious path, not all life sciences

en-us

22:44

Patient-focused manufacturing models for personalised...

pharmaphorum Podcast ·

2025/02/28

Unique, patient-focused manufacturing models are needed to scale up innovative cell therapies for cancer and one company, CTMC, is challenging the status quo to achieve this and get them to patients.In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Jason Bock, co-founder and CEO of CTMC, a first-of-its-kind cell therapy engine aiming to advance novel scientific breakthroughs into medicines developed rapidly and robustly to - ultimately - end cancer. Taking learnings from the

en-us

18:13

On specialty pharmacies and prior authorisations

pharmaphorum Podcast ·

2025/02/26

Prior authorisations (or PAs) have long put a burden on pharmacy and medical practices, ultimately causing delays for patients. In a new podcast, web editor Nicole Raleigh speaks with Andrew Burns, chief revenue officer at DrFirst, about the ramifications of delayed patient care when it comes to specialty medications. Exploring the current PA landscape, the conversation touches upon specialty pharmacy services and medications, helping to treat rare and complex medical conditions like cancer,

en-us

16:56

Paediatric rare diseases: Children are not small adults

pharmaphorum Podcast ·

2025/02/20

Around 75% of rare diseases are diagnosed in childhood, with most before the age of two. With 30% of rare disease patients dying before the age of five, the need for different treatment methods for children is clear.In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Dr Helen Thackray, chief R&D officer at biotech company BioCryst, as well as an alumnus of the Children’s National Medical Center. The conversation touches upon incentivisation for manufacturers to develop drugs to

en-us

25:27

Defining, building, and implementing in the next wave...

pharmaphorum Podcast ·

2025/02/13

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with two PharmaLex experts about navigating complex R&D processes to unleash the next wave of biopharma breakthroughs.PharmaLex’s Dr Christian Schneider, VP & Chief Medical Officer, Clinical Development Services, together with Dr Christelle Boileau, Director of Regulatory Development Strategy and IPD solution lead at PharmaLex, which is part of Cencora, explore the many challenges faced across the clinical trial landscape when

en-us

01:04:49

Insights from JP Morgan Healthcare 2025: Key trends...

pharmaphorum Podcast ·

2025/02/06

The JP Morgan Healthcare Conference remains one of the most influential events for the life sciences sector, setting the stage for major deal-making, investment trends, and strategic shifts that will define the year ahead.Keen to capture all the key trends and talking points from this year’s event, pharmaphorum editor-in-chief, Jonah Comstock, hit the ground running in Philadelphia, live blogging key sessions and interviewing experts to find out what industry insiders foresee for 2025. In this

en-us

15:01

‘Show me the molecule’ – On synthetic biology and...

pharmaphorum Podcast ·

2025/02/04

Therapeutic antibodies are a vital weapon in combating diseases such as cancer, but developing these treatments through conventional methods is slow and unreliable.In a new pharmaphorum podcast, web editor Nicole Raleigh spoke with Dr James Field, founder and CEO of LabGenius, a drug discovery company pioneering the discovery of next-generation therapeutic antibodies in order to solve this predicament. Dr Field speaks to how can industry cut through the hype that surrounds AI and optimally assess

en-us

29:03

Simulated clinical trial populations and AI scalability

pharmaphorum Podcast ·

2025/01/30

AI might still be in the modish buzzword stage, but discussions exploring the potential for its scaling within life sciences are critical.In a new pharmaphorum podcast with ZS Associates’ Sharon Karlsberg, principal and leader of oncology solutions, and Brandi Davis-Dusenbery, principal and partner, web editor Nicole Raleigh explores the potential for scaling advanced technologies in the biopharmaceutical industry. From digital twins and insilico modelling and the potential to reduce

en-us

15:43

Rare disease and the women's health gap

pharmaphorum Podcast ·

2025/01/23

For women with rare diseases, they often face a double jeopardy, where many of the symptoms they experience can be confused with and misdiagnosed as menopause.In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Jennifer Schranz, head of rare diseases at Ipsen, for a conversation focused on rare liver disease primary biliary cholangitis (PBC), which affects nine women for every one man, and the women’s health gap more generally. Schranz explains the importance of developing a more

en-us

21:32

From science fiction to reality: AI in drug development

pharmaphorum Podcast ·

2025/01/15

With about 92% of new drugs failing in human clinical trials, pharma companies face tremendous financial losses and, more importantly, development and delivery of potentially life-saving treatments are woefully delayed. In today’s pharmaphorum podcast, web editor Nicole Raleigh speaks with Dr Isaac Bentwich, CEO and founder of Quris.AI, about how AI could revolutionise preclinical research and accelerate the development of potentially life-saving drugs, safely. Exploring the notion of 3D organ

en-us

23:30

Precision medicine, NGS, and the quantum leap in...

pharmaphorum Podcast ·

2024/12/18

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Luca Quagliata, Vice President and Global Head of Medical and Scientific Affairs at Thermo Fisher Scientific, a company committed to advancing precision medicine, for a conversation on this space and a new frontier of biomarkers.Quagliata discusses Thermo Fisher’s ongoing collaboration with EVERSANA, pharmaphorum’s parent company, and that collaboration’s investigation of the impact of utilising electronic health record (EHR) data

en-us

280 results

Similar Podcasts

X Minus 1 - Old Time Radio Show

Inception Point Ai

Science, Spoken

WIRED

This Week in Space (Audio)

TWiT

DarshanTalks Podcast

Darshan Kulkarni

The Best of Coast to Coast AM

iHeartPodcasts and Coast to Coast AM